First Trust Advisors LP decreased its holdings in Teladoc Inc (NYSE:TDOC) by 19.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,294 shares of the health services provider’s stock after selling 21,668 shares during the period. First Trust Advisors LP owned about 0.16% of Teladoc worth $3,216,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the company. American International Group Inc. increased its holdings in shares of Teladoc by 8.1% in the 3rd quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock valued at $1,196,000 after purchasing an additional 2,697 shares during the period. Emerald Advisers Inc. PA increased its holdings in shares of Teladoc by 0.5% in the 4th quarter. Emerald Advisers Inc. PA now owns 566,096 shares of the health services provider’s stock valued at $19,728,000 after purchasing an additional 2,784 shares during the period. SG Americas Securities LLC acquired a new position in shares of Teladoc in the 4th quarter valued at about $101,000. Brown Advisory Inc. increased its holdings in shares of Teladoc by 38.3% in the 3rd quarter. Brown Advisory Inc. now owns 10,521 shares of the health services provider’s stock valued at $348,000 after purchasing an additional 2,915 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Teladoc by 7.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 48,941 shares of the health services provider’s stock valued at $1,622,000 after purchasing an additional 3,442 shares during the period.
A number of equities analysts have recently weighed in on TDOC shares. Canaccord Genuity upped their target price on Teladoc from $42.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Oppenheimer upped their target price on Teladoc from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Tuesday, November 21st. Chardan Capital restated a “buy” rating and issued a $47.00 price objective (down previously from $48.00) on shares of Teladoc in a report on Wednesday, February 28th. ValuEngine upgraded Teladoc from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $35.00 price objective (up previously from $31.00) on shares of Teladoc in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $40.71.
In other Teladoc news, President Peter A. Mcclennen sold 27,533 shares of the company’s stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $43.01, for a total transaction of $1,184,194.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Hirschhorn sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $39.60, for a total value of $3,960,000.00. Following the sale, the chief financial officer now directly owns 98,960 shares of the company’s stock, valued at approximately $3,918,816. The disclosure for this sale can be found here. Insiders have sold 324,494 shares of company stock valued at $12,935,147 in the last ninety days. Company insiders own 4.47% of the company’s stock.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.